Introduction
Methods
Study population
Clinical and patient-reported outcome measures
Data analysis
Results
Patient characteristics
Patient characteristics | n (%) / mean (SD) n = 424 |
---|---|
Female | 98 (23.1%) |
Age in years | 68.7 (9.1) |
Age at first symptom onset in years | 64.9 (10.3) |
Age at diagnosis in years | 66.8 (9.7) |
Duration since first symptoms in years | 3.7 (4.1) |
Disease duration in months | 2.0 (2.7) |
< 3 months | 124 (29.5%) |
3 to < 6 months | 39 (9.3%) |
More than 6 months | 258 (61.3%) |
Smoking status | |
Never | 161 (38.0%) |
Former stopped | 256 (60.4%) |
Current | 7 (1.7%) |
Number of comorbidities | |
None | 95 (22.4%) |
1 | 124 (29.3%) |
2 | 107 (25.2%) |
3 | 63 (14.9%) |
4+ | 35 (8.3%) |
NHYA | |
I | 28 (14.7%) |
II | 81 (42.6%) |
III | 76 (40.0%) |
IV | 5 (2.6%) |
Six-minute walk distance (m) | 287.7 (199.6) |
% FEV1 | 68.3 (17.4) |
% FVC | 36.1 (15.9) |
% DLCO | 75.9 (19.4) |
GAP index | 4.7 (1.4) |
Stage I | 72 (18.8%) |
Stage II | 203 (53.0%) |
Stage III | 108 (28.2%) |
Overall physician’s judgement of clinical course of IPF | |
Stable disease | 166 (39.2%) |
Slow progression | 123 (29.0%) |
Rapid progression | 31 (7.3%) |
No judgement possible | 104 (24.5%) |
SGRQ | 45.9 (19.7) |
SGRQ symptoms | 55.9 (21.0) |
SGRQ activity | 59.7 (23.6) |
SGRQ impacts | 34.8 (20.7) |
UCSD-SOBQ | 43.9 (28.8) |
EQ-5D VAS | 62.6 (18.5) |
WHO-5 | 14.8 (5.7) |
Change in QoL over time and associations to clinical parameters during follow up
SGRQ total | EQ 5D VAS | UCSD-SOBQ | WHO-5 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
beta | 95% CI | p-value | beta | 95% CI | p-value | beta | 95% CI | p-value | beta | 95% CI | p-value | |
Female sex | 5.42 | 1.13; 9.71 | 0.013 | −3.36 | −6.90; 0.18 | 0.063 | 13.56 | 6.41; 20.72 | < 0.001 | − 1.47 | −2.60; − 0.33 | 0.011 |
Age | 0.00 | −0.19; 0.20 | 0.963 | −0.18 | − 0.34; − 0.02 | 0.029 | 0.35 | 0.04; 0.66 | 0.026 | −0.05 | − 0.10; 0.00 | 0.074 |
Age at first symptom onset in years | −0.10 | − 0.28; 0.08 | 0.285 | − 0.08 | − 0.22; 0.07 | 0.323 | 0.17 | − 0.11; 0.46 | 0.238 | − 0.03 | − 0.07; 0.02 | 0.299 |
Age at diagnosis in years | −0.09 | − 0.28; 0.09 | 0.320 | − 0.08 | − 0.23; 0.07 | 0.290 | 0.18 | − 0.11; 0.48 | 0.227 | − 0.02 | − 0.07; 0.03 | 0.400 |
Duration since first symptoms in years | 0.73 | 0.28; 1.18 | 0.002 | −0.51 | −0.89; − 0.13 | 0.008 | 0.71 | − 0.04; 1.46 | 0.062 | − 0.09 | − 0.21; 0.03 | 0.139 |
Disease duration in months | 1.36 | 0.70; 2.02 | < 0.001 | −1.10 | − 1.65; −0.55 | < 0.001 | 1.70 | 0.64; 2.77 | 0.002 | −0.25 | −0.43; − 0.08 | 0.005 |
< 3 months | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
3 to < 6 months | −2.63 | −9.30; 4.04 | 0.440 | 1.30 | −4.28; 6.89 | 0.647 | −4.48 | −16.06; 7.11 | 0.449 | 0.54 | −1.27; 2.34 | 0.560 |
More than 6 months | 6.54 | 2.53; 10.55 | 0.001 | −5.10 | −8.43; − 1.76 | 0.003 | 8.43 | 1.74; 15.12 | 0.014 | −0.68 | −1.76; 0.40 | 0.215 |
Number of comorbidities | ||||||||||||
None | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
1 | 3.55 | −1.37; 8.47 | 0.157 | −5.19 | −9.23; − 1.16 | 0.012 | 9.93 | 2.05; 17.80 | 0.013 | −0.86 | −2.16; 0.44 | 0.195 |
2 | 4.49 | −0.63; 9.61 | 0.086 | −6.46 | −10.66; −2.26 | 0.003 | 10.11 | 1.88; 18.34 | 0.016 | −1.02 | −2.37; 0.33 | 0.140 |
3 | 5.87 | −0.04; 11.78 | 0.051 | −7.75 | − 12.62; −2.88 | 0.002 | 15.37 | 5.74; 24.99 | 0.002 | −1.98 | −3.55; −0.41 | 0.013 |
4+ | 17.18 | 10.14; 24.23 | < 0.001 | −14.99 | −20.88; −9.11 | < 0.001 | 33.06 | 20.77; 45.35 | < 0.001 | −4.35 | −6.24; −2.46 | < 0.001 |
NHYA | ||||||||||||
I | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
II | 16.07 | 9.16; 22.98 | < 0.001 | −12.61 | −19.06; −6.15 | < 0.001 | 22.28 | 10.78; 33.77 | < 0.001 | −1.86 | −3.92; 0.21 | 0.078 |
III | 26.95 | 19.97; 33.93 | < 0.001 | −18.00 | −24.49; − 11.50 | < 0.001 | 38.29 | 26.65; 49.92 | < 0.001 | −3.82 | −5.90; − 1.75 | < 0.001 |
IV | 33.28 | 16.44; 50.13 | < 0.001 | −27.35 | −41.90; − 12.81 | < 0.001 | 51.63 | 24.63; 78.64 | < 0.001 | −8.69 | −13.43; − 3.95 | < 0.001 |
6MWD (m) | − 0.01 | − 0.01; 0.00 | 0.217 | 0.00 | 0.00; 0.01 | 0.313 | −0.01 | − 0.03; 0.00 | 0.109 | 0.00 | 0.00; 0.00 | 0.423 |
FEV1% predicted | −0.55 | −0.62; − 0.49 | < 0.001 | 0.43 | 0.37; 0.49 | < 0.001 | − 0.80 | − 0.91; − 0.70 | < 0.001 | 0.09 | 0.07; 0.11 | < 0.001 |
FVC % predicted | − 0.60 | − 0.66; − 0.53 | < 0.001 | 0.46 | 0.39; 0.53 | < 0.001 | −0.89 | −1.00; − 0.78 | < 0.001 | 0.11 | 0.09; 0.13 | < 0.001 |
DLCO % predicted | −0.26 | − 0.31; − 0.20 | < 0.001 | 0.26 | 0.20; 0.33 | < 0.001 | − 0.35 | − 0.44; − 0.25 | < 0.001 | 0.04 | 0.02; 0.06 | < 0.001 |
Change in FVC % predicted between baseline and 1-year follow-up | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 3.71 | −0.55; 7.97 | 0.087 | −2.90 | −6.58; 0.77 | 0.122 | 4.08 | −3.13; 11.29 | 0.267 | −0.51 | −1.67; 0.65 | 0.393 |
Decrease by > 10% | 9.08 | 2.48; 15.67 | 0.007 | −8.07 | −13.81; −2.33 | 0.006 | 11.24 | 0.32; 22.16 | 0.044 | −1.30 | −3.09; 0.50 | 0.156 |
Change in DLCO % predicted between baseline and 1-year follow-up | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 5.46 | 0.85; 10.08 | 0.020 | −0.41 | −4.43; 3.60 | 0.841 | 10.46 | 2.85; 18.07 | 0.007 | −0.37 | −1.62; 0.88 | 0.561 |
Decrease by > 10% | 7.79 | 0.85; 14.73 | 0.028 | −3.93 | −9.96; 2.10 | 0.201 | 10.74 | −0.73; 22.21 | 0.067 | −0.40 | −2.28; 1.47 | 0.673 |
Change in FVC % predicted between baseline and last follow-up | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 3.44 | −1.04; 7.92 | 0.133 | −3.30 | −7.08; 0.48 | 0.087 | 3.18 | −4.45; 10.81 | 0.414 | −0.22 | −1.44; 0.99 | 0.719 |
Decrease by > 10% | 7.47 | 2.11; 12.83 | 0.006 | −6.50 | −11.02; − 1.99 | 0.005 | 8.80 | −0.15; 17.75 | 0.054 | −0.87 | −2.32; 0.59 | 0.242 |
Change in DLCO % predicted between baseline and last follow-up | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 4.41 | −0.52; 9.35 | 0.080 | −1.42 | −5.59; 2.75 | 0.505 | 11.09 | 2.94; 19.23 | 0.008 | −0.44 | −1.77; 0.89 | 0.518 |
Decrease by > 10% | 5.10 | −0.51; 10.72 | 0.075 | −2.47 | −7.18; 2.25 | 0.305 | 8.24 | −0.88; 17.36 | 0.077 | −0.30 | −1.80; 1.21 | 0.701 |
GAP index | 3.29 | 1.95; 4.64 | < 0.001 | −3.41 | −4.50; −2.33 | < 0.001 | 6.47 | 4.36; 8.58 | < 0.001 | −0.50 | − 0.86; − 0.14 | 0.007 |
Stage I | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Stage II | 5.69 | 0.74; 10.63 | 0.024 | −7.04 | −11.00; −3.08 | < 0.001 | 16.51 | 8.69; 24.34 | < 0.001 | −0.92 | −2.25; 0.41 | 0.177 |
Stage III | 12.93 | 7.42; 18.45 | < 0.001 | −13.51 | − 17.96; −9.07 | < 0.001 | 25.78 | 17.08; 34.47 | < 0.001 | − 1.79 | −3.27; −0.30 | 0.019 |
Overall physician’s judgement of clinical course of IPF | ||||||||||||
Stable disease | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Slow progression | 7.79 | 3.51; 12.06 | < 0.001 | −3.52 | −7.14; 0.10 | 0.056 | 11.13 | 4.04; 18.21 | 0.002 | −1.08 | −2.23; 0.08 | 0.068 |
Rapid progression | 13.16 | 6.22; 20.11 | < 0.001 | −9.52 | −15.39; −3.65 | 0.001 | 19.89 | 8.32; 31.47 | 0.001 | −2.72 | −4.61; −0.83 | 0.005 |
No judgement possible | −0.39 | −4.93; 4.15 | 0.865 | 1.33 | −2.43; 5.09 | 0.487 | 1.72 | −5.72; 9.15 | 0.651 | −0.01 | −1.23; 1.20 | 0.986 |
Association of QoL and mortality
SGRQ total | EQ-5D VAS | UCSD-SOBQ | WHO-5 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
A) Multivariable model including QoL at last available follow-up | ||||||||||||
QoL at last available follow-up a | 1.12 | 1.06; 1.18 | < 0.001 | 0.91 | 0.87; 0.96 | 0.001 | 1.14 | 1.08; 1.20 | < 0.001 | 0.83 | 0.69; 0.99 | 0.048 |
Age a | 1.32 | 1.14; 1.54 | < 0.001 | 1.30 | 1.12; 1.51 | 0.001 | 1.27 | 1.09; 1.48 | 0.002 | 1.25 | 1.07; 1.46 | 0.006 |
Number of comorbidities | ||||||||||||
0 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
1 | 2.40 | 1.15; 5.01 | 0.02 | 1.93 | 0.98; 3.77 | 0.057 | 2.51 | 0.92; 6.81 | 0.071 | 2.03 | 0.93; 4.41 | 0.075 |
2 | 2.10 | 1.02; 4.32 | 0.043 | 1.62 | 0.83; 3.19 | 0.161 | 2.40 | 0.90; 6.40 | 0.079 | 2.24 | 1.05; 4.80 | 0.038 |
3 | 2.78 | 1.26; 6.09 | 0.011 | 2.15 | 1.02; 4.53 | 0.043 | 3.16 | 0.99; 10.05 | 0.052 | 2.31 | 0.97; 5.46 | 0.057 |
4+ | 1.95 | 0.69; 5.49 | 0.205 | 1.98 | 0.77; 5.07 | 0.155 | 1.30 | 0.29; 5.86 | 0.734 | 2.80 | 1.00; 7.86 | 0.051 |
Change in FVC % predicted | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 1.63 | 0.98; 2.71 | 0.058 | 1.60 | 0.97; 2.64 | 0.066 | 1.41 | 0.75; 2.64 | 0.286 | 1.75 | 1.01; 3.03 | 0.047 |
Decrease by > 10% | 2.34 | 1.18; 4.62 | 0.015 | 2.29 | 1.16; 4.51 | 0.017 | 2.14 | 0.87; 5.26 | 0.096 | 2.70 | 1.32; 5.53 | 0.007 |
Hospitalisation | 1.26 | 0.80; 1.97 | 0.322 | 1.54 | 0.98; 2.40 | 0.06 | 1.00 | 0.57; 1.74 | 0.994 | 1.29 | 0.81; 2.06 | 0.286 |
Overall physician’s judgement of clinical course of IPF | ||||||||||||
Stable disease | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Slow progression | 1.48 | 0.92; 2.38 | 0.106 | 1.70 | 1.08; 2.69 | 0.022 | 1.30 | 0.71; 2.37 | 0.399 | 1.91 | 1.16; 3.17 | 0.012 |
Rapid progression | 0.97 | 0.46; 2.04 | 0.933 | 1.18 | 0.55; 2.53 | 0.674 | 1.06 | 0.46; 2.42 | 0.896 | 1.25 | 0.53; 2.95 | 0.617 |
No judgement possible | 0.89 | 0.46; 1.74 | 0.743 | 0.98 | 0.52; 1.84 | 0.95 | 1.26 | 0.54; 2.93 | 0.588 | 0.94 | 0.47; 1.91 | 0.871 |
B) Multivariable model including change in QoL between baseline and last available follow-up | ||||||||||||
Change in QoL between baseline and last available follow-up a | 1.05 | 0.98; 1.13 | 0.148 | 0.97 | 0.91; 1.04 | 0.364 | 1.07 | 0.98; 1.16 | 0.127 | 0.85 | 0.68; 1.07 | 0.165 |
Age a | 1.30 | 1.11; 1.52 | 0.001 | 1.31 | 1.12; 1.53 | 0.001 | 1.26 | 1.02; 1.56 | 0.031 | 1.26 | 1.07; 1.48 | 0.006 |
Number of comorbidities | ||||||||||||
0 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
1 | 1.98 | 0.97; 4.04 | 0.061 | 1.83 | 0.92; 3.63 | 0.084 | 2.03 | 0.71; 5.84 | 0.187 | 1.93 | 0.89; 4.20 | 0.096 |
2 | 1.85 | 0.90; 3.79 | 0.092 | 1.70 | 0.85; 3.40 | 0.135 | 2.01 | 0.65; 6.21 | 0.226 | 2.14 | 0.99; 4.63 | 0.054 |
3 | 2.40 | 1.10; 5.24 | 0.028 | 2.25 | 1.06; 4.76 | 0.035 | 3.68 | 1.17; 11.55 | 0.026 | 2.18 | 0.91; 5.23 | 0.082 |
4+ | 2.04 | 0.75; 5.57 | 0.165 | 2.27 | 0.87; 5.92 | 0.093 | 1.54 | 0.26; 9.06 | 0.634 | 2.99 | 1.09; 8.22 | 0.034 |
Change in FVC % predicted | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 1.69 | 1.02; 2.82 | 0.044 | 1.65 | 0.99; 2.76 | 0.055 | 1.11 | 0.57; 2.14 | 0.762 | 1.67 | 0.95; 2.91 | 0.073 |
Decrease by > 10% | 2.16 | 1.08; 4.31 | 0.029 | 2.26 | 1.14; 4.50 | 0.02 | 1.72 | 0.71; 4.14 | 0.227 | 2.43 | 1.18; 5.00 | 0.015 |
Hospitalisation | 1.35 | 0.85; 2.13 | 0.202 | 1.54 | 0.98; 2.42 | 0.059 | 1.30 | 0.68; 2.45 | 0.427 | 1.30 | 0.81; 2.08 | 0.285 |
Overall physician’s judgement of clinical course of IPF | ||||||||||||
Stable disease | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Slow progression | 1.69 | 1.05; 2.73 | 0.03 | 1.83 | 1.14; 2.94 | 0.012 | 1.38 | 0.67; 2.85 | 0.381 | 1.89 | 1.15; 3.12 | 0.013 |
Rapid progression | 1.42 | 0.69; 2.91 | 0.341 | 1.63 | 0.76; 3.46 | 0.207 | 1.27 | 0.47; 3.41 | 0.636 | 1.38 | 0.61; 3.12 | 0.439 |
No judgement possible | 0.97 | 0.49; 1.92 | 0.922 | 0.96 | 0.50; 1.83 | 0.902 | 1.24 | 0.52; 2.95 | 0.622 | 0.83 | 0.39; 1.77 | 0.635 |
SGRQ | EQ-5D VAS | UCSD-SOBQ | WHO-5 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
beta | 95% CI | p-value | beta | 95% CI | p-value | beta | 95% CI | p-value | beta | 95% CI | p-value | |
Any hospitalisation | 3.95 | 0.35; 7.56 | 0.032 | − 0.53 | −3.70; 2.64 | 0.743 | 8.41 | 2.46; 14.37 | 0.006 | −0.56 | − 1.60; 0.48 | 0.292 |
Age | −0.04 | − 0.26; 0.17 | 0.702 | − 0.21 | − 0.39; − 0.02 | 0.026 | 0.26 | − 0.08; 0.61 | 0.129 | − 0.05 | − 0.11; 0.02 | 0.141 |
Number of comorbidities | ||||||||||||
0 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
1 | −1.61 | −7.37; 4.15 | 0.584 | −0.40 | −5.40; 4.60 | 0.875 | 0.31 | −8.64; 9.26 | 0.946 | 0.29 | −1.25; 1.83 | 0.714 |
2 | 1.82 | −3.91; 7.56 | 0.533 | −3.01 | −8.19; 2.17 | 0.255 | 5.47 | −3.72; 14.66 | 0.243 | 0.20 | −1.36; 1.76 | 0.801 |
3 | 3.36 | −2.91; 9.62 | 0.293 | −4.07 | −9.51; 1.38 | 0.143 | 7.11 | −2.70; 16.93 | 0.155 | −0.96 | −2.63; 0.71 | 0.259 |
4+ | 11.42 | 4.99; 17.85 | 0.001 | −10.18 | − 16.28; −4.07 | 0.001 | 22.96 | 11.27; 34.65 | < 0.001 | −2.64 | −5.02; −0.27 | 0.029 |
Change in FVC % predicted | ||||||||||||
Stable/increase | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
Decrease by 0 to 10% | 3.70 | −0.10; 7.51 | 0.057 | −2.93 | −6.17; 0.32 | 0.077 | 4.60 | −1.67; 10.87 | 0.151 | −0.51 | −1.62; 0.61 | 0.375 |
Decrease by > 10% | 8.08 | 2.23; 13.93 | 0.007 | −6.11 | −11.14; − 1.08 | 0.017 | 8.91 | −0.23; 18.05 | 0.056 | −0.97 | −2.59; 0.66 | 0.242 |
Overall physician’s judgement of clinical course of IPF | ||||||||||||
Stable disease | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
Slow progression | 7.15 | 4.88; 9.42 | < 0.001 | −7.24 | − 10.05; −4.44 | < 0.001 | 10.65 | 5.96; 15.35 | < 0.001 | −1.62 | −2.34; − 0.89 | < 0.001 |
Rapid progression | 22.68 | 16.83; 28.52 | < 0.001 | − 26.37 | −32.73; − 20.01 | < 0.001 | 33.57 | 24.66; 42.48 | < 0.001 | −6.35 | −8.31; −4.40 | < 0.001 |
No judgement possible | 3.02 | 0.33; 5.70 | 0.027 | −2.15 | −5.16; 0.87 | 0.163 | 1.70 | −2.96; 6.35 | 0.475 | −1.25 | −2.11; −0.40 | 0.004 |
Hospitalisation by exacerbation | 5.35 | 0.64; 10.07 | 0.026 | −1.56 | −5.78; 2.65 | 0.468 | 10.89 | 2.72; 19.05 | 0.009 | −0.78 | −2.32; 0.76 | 0.320 |
Age | 0.04 | −0.24; 0.31 | 0.791 | −0.37 | − 0.59; − 0.15 | 0.001 | 0.40 | − 0.02; 0.82 | 0.062 | − 0.04 | −0.12; 0.04 | 0.383 |
Number of comorbidities | ||||||||||||
0 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
1 | −0.33 | −6.99; 6.32 | 0.922 | −1.35 | −7.22; 4.51 | 0.651 | 1.41 | −8.79; 11.61 | 0.786 | 0.23 | −1.58; 2.04 | 0.804 |
2 | 2.93 | −3.86; 9.72 | 0.397 | −2.43 | −8.49; 3.64 | 0.433 | 6.77 | −4.36; 17.89 | 0.233 | −0.09 | −2.05; 1.88 | 0.930 |
3 | 3.52 | −3.89; 10.93 | 0.352 | −1.79 | −8.17; 4.60 | 0.583 | 7.09 | −5.08; 19.27 | 0.253 | −0.94 | −3.15; 1.26 | 0.403 |
4+ | 13.15 | 5.95; 20.36 | < 0.001 | −8.90 | −15.99; − 1.82 | 0.014 | 21.07 | 8.29; 33.84 | 0.001 | −2.60 | −5.56; 0.36 | 0.085 |
Change in FVC % predicted | ||||||||||||
Stable/increase | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
Decrease by 0 to 10% | 4.08 | −0.73; 8.88 | 0.096 | −4.12 | −8.39; 0.15 | 0.059 | 6.63 | −1.24; 14.50 | 0.099 | −0.75 | −2.17; 0.67 | 0.300 |
Decrease by > 10% | 7.49 | 0.66; 14.32 | 0.032 | −4.05 | −10.00; 1.90 | 0.182 | 9.98 | −0.91; 20.86 | 0.072 | −1.04 | −2.79; 0.72 | 0.247 |
Overall physician’s judgement of clinical course of IPF | ||||||||||||
Stable disease | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
Slow progression | 6.65 | 3.84; 9.46 | < 0.001 | −8.90 | −12.49; −5.31 | < 0.001 | 9.98 | 3.38; 16.58 | 0.003 | −1.63 | −2.55; −0.70 | 0.001 |
Rapid progression | 24.23 | 17.19; 31.26 | < 0.001 | −27.75 | −36.15; −19.34 | < 0.001 | 33.78 | 22.82; 44.75 | < 0.001 | −6.67 | −9.06; −4.29 | < 0.001 |
No judgement possible | 2.36 | −0.77; 5.49 | 0.139 | −1.16 | −4.97; 2.66 | 0.552 | −0.76 | −6.46; 4.94 | 0.794 | −0.98 | −2.00; 0.03 | 0.058 |